1. The New Decade Of Healthcare: Can We Evolve Post-Market Platforms To Inform Coverage Decisions? FDA CMS SUMMIT • Washington, DC • December 9, 2010 Nathan White, CPC Executive Director, Reimbursement Strategy inVentiv Health
2. The pharmaceutical industry is embarking on a perilous journey, bracing itself for the perfect storm The inefficiencies of managing vendor and consultant relationships The complexities of proving value to payers The uncertainties of healthcare reform What does the perfect storm look like
3. Medicare and Medicaid expansion Comparative Effectiveness Research Increasing premiums and cost sharing Insurance exchanges Access to affordable coverage Premium subsidies Doughnut hole rebates Safety Outcomes Quality
4. Patient Protection and Affordable Care Act Uncertainties with new Congress Future legislative changes Expansion of coverage Cost Containment Quality and outcomes
5.
6.
7.
8. Federal Initiatives Using PRO SOURCES: www.nihpromis.org ; http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effective-health-care-program1/about-the-decide-network/ PROMIS®: Patient Reported Outcomes Measurement System NIH-funded development of PRO tools through primary research sites & coordinating centers AHRQ DEcIDE Network Group of Principal Investigators, working through 13 Research Centers, conducts studies on outcomes, effectiveness, safety and usefulness of medical treatments
9.
10.
11.
12.
13.
14.
15.
16.
17.
18. To schedule a complimentary on-site consultation with the embarx BridgeTeam, contact : Nathan White, CPC (703) 662-1851 [email_address]
Notes de l'éditeur
Strattera ® (atomoxetine HCl) is indicated for the treatment of attention-deficit/hyperactivity disorder in children aged 6 and older, adolescents, and adults. See Important Safety Information, including Boxed Warning, and full Prescribing Information for Strattera, available during this presentation. For Internal Use Only. Not for Use in Detailing. Optimizing ADHD Treatment With Strattera ® “Are we there yet?”
Strattera ® (atomoxetine HCl) is indicated for the treatment of attention-deficit/hyperactivity disorder in children aged 6 and older, adolescents, and adults. See Important Safety Information, including Boxed Warning, and full Prescribing Information for Strattera, available during this presentation. For Internal Use Only. Not for Use in Detailing. Optimizing ADHD Treatment With Strattera ® “Are we there yet?”